AVDL · As filed with the SEC

Avadel Pharmaceuticals balance sheet, by quarter

The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONDENSED CONSOLIDATED BALANCE SHEETS · USD thousands

USD thousands	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	79,813	63,402	56,370	51,371
Marketable securities	11,764	18,145	10,114	22,406
Accounts receivable, net	42,444	40,631	41,581	34,097
Inventories	23,905	23,484	20,406	20,298
Prepaid expenses and other current assets	14,300	13,443	10,787	6,036
Total current assets	172,226	159,105	139,258	134,208
Property and equipment, net	467	472	307	453
Operating lease right-of-use assets	2,544	2,721	2,896	1,702
Goodwill	16,836	16,836	16,836	16,836
Other non-current assets	7,375	8,023	8,652	11,037
Total assets	199,448	187,157	167,949	164,236
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of operating lease liability	740	723	706	582
Accounts payable	12,581	10,114	9,116	7,328
Accrued expenses	44,156	42,776	40,917	40,651
Other current liabilities	5,010	3,452	194	273
Total current liabilities	62,487	57,065	50,933	48,834
Long-term operating lease liability	1,810	2,002	2,189	1,122
Royalty financing obligation	34,828	35,318	35,518	35,249
Other non-current liabilities	2,098	2,063	5,239	5,183
Total liabilities	101,223	96,448	93,879	90,388
Shareholders’ equity:
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; zero issued and outstanding at September 30, 2025 and December 31, 2024	0	0	0	0
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 97,235 issued and outstanding at September 30, 2025 and 96,518 issued and outstanding at December 31, 2024	972	967	966	965
Additional paid-in capital	910,391	902,970	896,663	891,791
Accumulated deficit	(789,562)	(789,582)	(799,247)	(794,328)
Accumulated other comprehensive loss	(23,576)	(23,646)	(24,312)	(24,580)
Total shareholders’ equity	98,225	90,709	74,070	73,848
Total liabilities and shareholders’ equity	199,448	187,157	167,949	164,236

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.